Stock Track | Ligand Pharmaceuticals Plunges 5.06% as 2024 Results and Acquisition Come Under Scrutiny

Stock Track

Mar 03, 2025

Ligand Pharmaceuticals (NASDAQ: LGND) saw its stock price plummet by 5.06% in the pre-market trading session on Monday, March 3rd, 2025.

The drop in Ligand's share price can be attributed to the company's recently reported 2024 financial results and its acquisition of a royalty stake in Castle Creek Biosciences, a gene therapy company targeting a rare skin disease.

While Ligand reported a 27% increase in revenues and a 41% rise in adjusted earnings per share for 2024, the company's financial performance seems to have failed to meet investors' expectations. The company's guidance for 2025, projecting low-teens revenue growth and earnings per share of $6.00 to $6.25, also appears to have disappointed the market.

Additionally, Ligand's announcement of its participation in a $75 million royalty financing deal for Castle Creek Biosciences, aimed at supporting the latter's Phase III study of a gene therapy candidate for dystrophic epidermolysis bullosa (DEB), a rare skin disorder, has likely raised concerns among investors regarding the potential risks and returns associated with this investment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1113131736"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1113131736\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1113131736?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-03 23:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113131736","market":"us","top_or_hot":-1,"title":"Stock Track | Ligand Pharmaceuticals Plunges 5.06% as 2024 Results and Acquisition Come Under Scrutiny","media":"Stock Track","content":"<p>Ligand Pharmaceuticals (NASDAQ: LGND) saw its stock price plummet by 5.06% in the pre-market trading session on Monday, March 3rd, 2025.</p>\n\n<p>The drop in Ligand's share price can be attributed to the company's recently reported 2024 financial results and its acquisition of a royalty stake in Castle Creek Biosciences, a gene therapy company targeting a rare skin disease.</p>\n\n<p>While Ligand reported a 27% increase in revenues and a 41% rise in adjusted earnings per share for 2024, the company's financial performance seems to have failed to meet investors' expectations. The company's guidance for 2025, projecting low-teens revenue growth and earnings per share of $6.00 to $6.25, also appears to have disappointed the market.</p>\n\n<p>Additionally, Ligand's announcement of its participation in a $75 million royalty financing deal for Castle Creek Biosciences, aimed at supporting the latter's Phase III study of a gene therapy candidate for dystrophic epidermolysis bullosa (DEB), a rare skin disorder, has likely raised concerns among investors regarding the potential risks and returns associated with this investment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ligand Pharmaceuticals Plunges 5.06% as 2024 Results and Acquisition Come Under Scrutiny</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ligand Pharmaceuticals Plunges 5.06% as 2024 Results and Acquisition Come Under Scrutiny\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-03 23:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Ligand Pharmaceuticals (NASDAQ: LGND) saw its stock price plummet by 5.06% in the pre-market trading session on Monday, March 3rd, 2025.</p>\n\n<p>The drop in Ligand's share price can be attributed to the company's recently reported 2024 financial results and its acquisition of a royalty stake in Castle Creek Biosciences, a gene therapy company targeting a rare skin disease.</p>\n\n<p>While Ligand reported a 27% increase in revenues and a 41% rise in adjusted earnings per share for 2024, the company's financial performance seems to have failed to meet investors' expectations. The company's guidance for 2025, projecting low-teens revenue growth and earnings per share of $6.00 to $6.25, also appears to have disappointed the market.</p>\n\n<p>Additionally, Ligand's announcement of its participation in a $75 million royalty financing deal for Castle Creek Biosciences, aimed at supporting the latter's Phase III study of a gene therapy candidate for dystrophic epidermolysis bullosa (DEB), a rare skin disorder, has likely raised concerns among investors regarding the potential risks and returns associated with this investment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LGND","symbol_name":"Ligand Pharmaceuticals Inc.","start_time":0,"source_url":"","article_id":"1113131736","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113131736","pubTimestamp":1741014994,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Ligand Pharmaceuticals  saw its stock price plummet by 5.06% in the pre-market trading session on Monday, March 3rd, 2025.The drop in Ligand's share price can be attributed to the company's recently reported 2024 financial results and its acquisition of a royalty stake in Castle Creek Biosciences, a gene therapy company targeting a rare skin disease.While Ligand reported a 27% increase in revenues and a 41% rise in adjusted earnings per share for 2024, the company's financial performance seems t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LGND":"Ligand Pharmaceuticals Inc."},"translate_title":"由于2024年业绩和收购受到审查，股票跟踪Ligand Pharmaceuticals暴跌5.06%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGND":1},"content_text":"Ligand Pharmaceuticals (NASDAQ: LGND) saw its stock price plummet by 5.06% in the pre-market trading session on Monday, March 3rd, 2025.\nThe drop in Ligand's share price can be attributed to the company's recently reported 2024 financial results and its acquisition of a royalty stake in Castle Creek Biosciences, a gene therapy company targeting a rare skin disease.\nWhile Ligand reported a 27% increase in revenues and a 41% rise in adjusted earnings per share for 2024, the company's financial performance seems to have failed to meet investors' expectations. The company's guidance for 2025, projecting low-teens revenue growth and earnings per share of $6.00 to $6.25, also appears to have disappointed the market.\nAdditionally, Ligand's announcement of its participation in a $75 million royalty financing deal for Castle Creek Biosciences, aimed at supporting the latter's Phase III study of a gene therapy candidate for dystrophic epidermolysis bullosa (DEB), a rare skin disorder, has likely raised concerns among investors regarding the potential risks and returns associated with this investment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"merge,movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}